GMP-engineered CAR-myeloid cells: overcoming allogeneic barriers in CNS tumors
Chimeric antigen receptor (CAR)-T therapy is limited in solid tumors by poor infiltration and immunosuppression, while myeloid cell translation is hindered by expansion bottlenecks and allogeneic MHC mismatch. Now, Yue et al. establish an expandable granulocyte-monocyte progenitor (GMP) platform that overcomes three lo...